<DOC>
	<DOCNO>NCT02326974</DOCNO>
	<brief_summary>This research study study combination drug possible treatment breast cancer test positive protein call HER2 . The name study intervention involve study : - Trastuzumab emtansine ( also call T-DM1 ) - Pertuzumab</brief_summary>
	<brief_title>T-DM1+Pertuzumab Pre-OP Early-Stage HER2+ BRCA</brief_title>
	<detailed_description>This research study Phase II clinical trial . Phase II clinical trial test safety effectiveness investigational intervention learn whether intervention work treat specific disease . `` Investigational '' mean intervention study . The FDA ( U.S. Food Drug Administration ) approve T-DM1 pre-operative use breast cancer approve us breast cancer . The FDA approve pertuzumab pre-operative treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<criteria>Patients must HER2positive Stage II III histologically confirm invasive carcinoma breast . A minimum tumor size 2 cm determine physical exam imaging require . HER2 positive , confirmed central testing ( Clarient lab ) : IHC 3+ and/or FISH positive base one three follow criterion : Singleprobe average HER2 copy number≥6.0 signals/cell OR Dualprobe HER2/CEP17 &lt; 2.0 average HER2 copy number ≥6.0 signals/cell OR Dualprobe HER2/CEP17 ratio ≥2.0 ER/PR determination require . Bilateral breast cancer allow cancer HER2positive . Patients multifocal multicentric disease eligible long one area meet eligibility criterion . Breast image include ipsilateral axilla . For subject clinically negative axilla , sentinel lymph node biopsy perform either preoperative therapy discretion subject 's physician . For subject clinically positive axilla , needle aspiration , core biopsy SLN procedure perform determine presence metastatic disease lymph node . Men woman ( menopausal status ) ≥ 18 year age ECOG performance status 0 1 Required laboratory value : ANC ≥1500/mm3 Hemoglobin ≥ 9 g/dl Platelets ≥100,000/mm3 Serum creatinine &lt; 1.5 X ULN ( institutional ) Total bilirubin ≤ 1.0 X ULN ( institutional ) For patient Gilbert syndrome , direct bilirubin within institutional normal range . AST ALT ≤ 1.5x ULN ( institutional ) Alkaline phosphatase ≤1.5x ULN ( institutional ) Documentation hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) serology require : include hepatitis B surface antigen ( HBsAg ) and/or total hepatitis B core antibody ( HBcAb ) addition HCV antibody test . Only patient test positive hep B/C virus : PTT/INR &lt; ULN ( institutional ) Left ventricular ejection fraction ( LVEF ) ≥ 55 % Premenopausal woman must negative serum pregnancy test , include woman tubal ligation woman less 12 month onset menopause . Women childbearing potential men partner childbearing potential must willing use one highly effective form nonhormonal contraception two effective form nonhormonal contraception patient and/or partner continue use duration study treatment 7 month last dose study treatment . Potent CYP3A4 inhibitor , ketoconazole erythromycin , avoid study treatment period TDM1 . Excessive alcohol intake avoid ( occasional use permit ) . Patients history ipsilateral DCIS eligible . Patients undergo breast conservation therapy ( i.e . lumpectomy ) must contraindications radiation therapy . Willing able sign inform consent . Willing provide tissue research purpose . Pregnant nursing woman due teratogenic potential study drug . Active , unresolved infection . Receipt intravenous antibiotic infection within 7 day prior enrollment . Patients active liver disease , example , due hepatitis B virus , hepatitis C virus , autoimmune hepatic disorder , sclerosing cholangitis . Uncontrolled hypertension ( systolic &gt; 180 mm Hg and/or diastolic &gt; 100 mm Hg ) clinically significant ( i.e . active ) cardiovascular disease : cerebrovascular accident/stroke myocardial infarction within 6 month prior first study medication , unstable angina , congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Grade II high , serious cardiac arrhythmia require medication . Significant symptom ( Grade ≥2 ) peripheral neuropathy . Other concurrent serious disease may interfere plan treatment , include severe pulmonary conditions/illness , uncontrolled infection , uncontrolled diabetes . Any prior treatment current breast cancer , include chemotherapy , hormonal therapy , radiation experimental therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>